vs
Side-by-side financial comparison of ALBANY INTERNATIONAL CORP (AIN) and AVANOS MEDICAL, INC. (AVNS). Click either name above to swap in a different company.
ALBANY INTERNATIONAL CORP is the larger business by last-quarter revenue ($321.2M vs $180.9M, roughly 1.8× AVANOS MEDICAL, INC.). ALBANY INTERNATIONAL CORP runs the higher net margin — 4.3% vs -0.7%, a 5.0% gap on every dollar of revenue. On growth, ALBANY INTERNATIONAL CORP posted the faster year-over-year revenue change (12.0% vs 0.7%). ALBANY INTERNATIONAL CORP produced more free cash flow last quarter ($51.4M vs $21.3M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 1.2%).
Albany International Corp is a global advanced materials and industrial technology company. It operates two core segments: Machine Clothing producing custom engineered fabrics for paper and other industrial manufacturing processes, and Engineered Composites developing high-performance composite components primarily for the aerospace and defense sectors, serving customers across North America, Europe, Asia and other global regions.
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
AIN vs AVNS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $321.2M | $180.9M |
| Net Profit | $13.9M | $-1.3M |
| Gross Margin | 31.1% | 47.5% |
| Operating Margin | 9.3% | 1.4% |
| Net Margin | 4.3% | -0.7% |
| Revenue YoY | 12.0% | 0.7% |
| Net Profit YoY | -21.5% | 99.7% |
| EPS (diluted) | $0.56 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $321.2M | $180.9M | ||
| Q3 25 | $261.4M | $177.8M | ||
| Q2 25 | $311.4M | $175.0M | ||
| Q1 25 | $288.8M | $167.5M | ||
| Q4 24 | $286.9M | $179.6M | ||
| Q3 24 | $298.4M | $170.4M | ||
| Q2 24 | $332.0M | $171.7M | ||
| Q1 24 | $313.3M | $166.1M |
| Q4 25 | $13.9M | $-1.3M | ||
| Q3 25 | $-97.8M | $-1.4M | ||
| Q2 25 | $9.2M | $-76.8M | ||
| Q1 25 | $17.4M | $6.6M | ||
| Q4 24 | $17.7M | $-397.3M | ||
| Q3 24 | $18.0M | $4.3M | ||
| Q2 24 | $24.6M | $1.8M | ||
| Q1 24 | $27.3M | $-900.0K |
| Q4 25 | 31.1% | 47.5% | ||
| Q3 25 | -19.1% | 48.4% | ||
| Q2 25 | 31.3% | 52.6% | ||
| Q1 25 | 33.4% | 53.6% | ||
| Q4 24 | 31.5% | 54.6% | ||
| Q3 24 | 30.3% | 54.5% | ||
| Q2 24 | 33.9% | 55.7% | ||
| Q1 24 | 34.7% | 57.1% |
| Q4 25 | 9.3% | 1.4% | ||
| Q3 25 | -44.6% | 0.1% | ||
| Q2 25 | 7.2% | -42.6% | ||
| Q1 25 | 9.8% | 6.1% | ||
| Q4 24 | 8.5% | -233.0% | ||
| Q3 24 | 8.4% | 7.0% | ||
| Q2 24 | 12.9% | 3.7% | ||
| Q1 24 | 12.4% | 2.4% |
| Q4 25 | 4.3% | -0.7% | ||
| Q3 25 | -37.4% | -0.8% | ||
| Q2 25 | 2.9% | -43.9% | ||
| Q1 25 | 6.0% | 3.9% | ||
| Q4 24 | 6.2% | -221.2% | ||
| Q3 24 | 6.0% | 2.5% | ||
| Q2 24 | 7.4% | 1.0% | ||
| Q1 24 | 8.7% | -0.5% |
| Q4 25 | $0.56 | $-0.02 | ||
| Q3 25 | $-3.37 | $-0.03 | ||
| Q2 25 | $0.31 | $-1.66 | ||
| Q1 25 | $0.56 | $0.14 | ||
| Q4 24 | $0.57 | $-8.64 | ||
| Q3 24 | $0.57 | $0.09 | ||
| Q2 24 | $0.79 | $0.04 | ||
| Q1 24 | $0.87 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $112.3M | $89.8M |
| Total DebtLower is stronger | $455.7M | $90.3M |
| Stockholders' EquityBook value | $726.2M | $778.2M |
| Total Assets | $1.7B | $1.1B |
| Debt / EquityLower = less leverage | 0.63× | 0.12× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $112.3M | $89.8M | ||
| Q3 25 | $108.3M | $70.5M | ||
| Q2 25 | $106.7M | $90.3M | ||
| Q1 25 | $119.4M | $97.0M | ||
| Q4 24 | $115.3M | $107.7M | ||
| Q3 24 | $127.2M | $89.0M | ||
| Q2 24 | $116.4M | $92.2M | ||
| Q1 24 | $125.4M | $75.8M |
| Q4 25 | $455.7M | $90.3M | ||
| Q3 25 | $480.6M | $93.4M | ||
| Q2 25 | $444.7M | $95.7M | ||
| Q1 25 | $416.4M | $98.0M | ||
| Q4 24 | $318.5M | $125.3M | ||
| Q3 24 | $362.2M | $152.6M | ||
| Q2 24 | $377.1M | $164.9M | ||
| Q1 24 | $439.1M | $167.2M |
| Q4 25 | $726.2M | $778.2M | ||
| Q3 25 | $739.3M | $778.0M | ||
| Q2 25 | $888.6M | $776.3M | ||
| Q1 25 | $900.0M | $839.4M | ||
| Q4 24 | $943.5M | $828.5M | ||
| Q3 24 | $991.0M | $1.2B | ||
| Q2 24 | $967.5M | $1.2B | ||
| Q1 24 | $967.5M | $1.2B |
| Q4 25 | $1.7B | $1.1B | ||
| Q3 25 | $1.7B | $1.1B | ||
| Q2 25 | $1.7B | $1.0B | ||
| Q1 25 | $1.7B | $1.1B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.8B | $1.7B | ||
| Q2 24 | $1.8B | $1.7B | ||
| Q1 24 | $1.8B | $1.7B |
| Q4 25 | 0.63× | 0.12× | ||
| Q3 25 | 0.65× | 0.12× | ||
| Q2 25 | 0.50× | 0.12× | ||
| Q1 25 | 0.46× | 0.12× | ||
| Q4 24 | 0.34× | 0.15× | ||
| Q3 24 | 0.37× | 0.12× | ||
| Q2 24 | 0.39× | 0.13× | ||
| Q1 24 | 0.45× | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.7M | $28.2M |
| Free Cash FlowOCF − Capex | $51.4M | $21.3M |
| FCF MarginFCF / Revenue | 16.0% | 11.8% |
| Capex IntensityCapex / Revenue | 6.9% | 3.8% |
| Cash ConversionOCF / Net Profit | 5.31× | — |
| TTM Free Cash FlowTrailing 4 quarters | $82.6M | $43.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $73.7M | $28.2M | ||
| Q3 25 | $43.9M | $14.0M | ||
| Q2 25 | $32.7M | $6.8M | ||
| Q1 25 | $2.1M | $25.7M | ||
| Q4 24 | $78.5M | $57.9M | ||
| Q3 24 | $47.0M | $23.0M | ||
| Q2 24 | $83.4M | $27.8M | ||
| Q1 24 | $9.6M | $-8.0M |
| Q4 25 | $51.4M | $21.3M | ||
| Q3 25 | $25.9M | $7.0M | ||
| Q2 25 | $18.8M | $-4.2M | ||
| Q1 25 | $-13.5M | $19.0M | ||
| Q4 24 | $60.2M | $53.1M | ||
| Q3 24 | $31.6M | $20.0M | ||
| Q2 24 | $63.6M | $21.9M | ||
| Q1 24 | $-17.3M | $-12.1M |
| Q4 25 | 16.0% | 11.8% | ||
| Q3 25 | 9.9% | 3.9% | ||
| Q2 25 | 6.0% | -2.4% | ||
| Q1 25 | -4.7% | 11.3% | ||
| Q4 24 | 21.0% | 29.6% | ||
| Q3 24 | 10.6% | 11.7% | ||
| Q2 24 | 19.2% | 12.8% | ||
| Q1 24 | -5.5% | -7.3% |
| Q4 25 | 6.9% | 3.8% | ||
| Q3 25 | 6.9% | 3.9% | ||
| Q2 25 | 4.5% | 6.3% | ||
| Q1 25 | 5.4% | 4.0% | ||
| Q4 24 | 6.4% | 2.7% | ||
| Q3 24 | 5.2% | 1.8% | ||
| Q2 24 | 6.0% | 3.4% | ||
| Q1 24 | 8.6% | 2.5% |
| Q4 25 | 5.31× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.56× | — | ||
| Q1 25 | 0.12× | 3.89× | ||
| Q4 24 | 4.44× | — | ||
| Q3 24 | 2.61× | 5.35× | ||
| Q2 24 | 3.39× | 15.44× | ||
| Q1 24 | 0.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIN
| Transferred At Point In Time | $176.5M | 55% |
| Engineered Composites Other | $99.3M | 31% |
| Engineered Composites ASC | $44.5M | 14% |
| Transferred Over Time | $1.0M | 0% |
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
